- Home
- NGNE vs CLW Comparison
NGNE vs CLW Comparison
Compare NGNE & CLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- CLW
- Stock Information
- Founded
- NGNE 2003
- CLW 2005
- Country
- NGNE United States
- CLW United States
- Employees
- NGNE N/A
- CLW N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- CLW Paper
- Sector
- NGNE Health Care
- CLW Basic Materials
- Exchange
- NGNE Nasdaq
- CLW Nasdaq
- Market Cap
- NGNE 325.3M
- CLW 348.3M
- IPO Year
- NGNE N/A
- CLW N/A
- Fundamental
- Price
- NGNE $19.95
- CLW $21.98
- Analyst Decision
- NGNE Strong Buy
- CLW Buy
- Analyst Count
- NGNE 7
- CLW 1
- Target Price
- NGNE $41.86
- CLW $36.00
- AVG Volume (30 Days)
- NGNE 113.3K
- CLW 197.2K
- Earning Date
- NGNE 08-11-2025
- CLW 11-03-2025
- Dividend Yield
- NGNE N/A
- CLW N/A
- EPS Growth
- NGNE N/A
- CLW 345.10
- EPS
- NGNE N/A
- CLW 12.12
- Revenue
- NGNE N/A
- CLW $1,550,400,000.00
- Revenue This Year
- NGNE N/A
- CLW $12.75
- Revenue Next Year
- NGNE N/A
- CLW $1.60
- P/E Ratio
- NGNE N/A
- CLW $1.76
- Revenue Growth
- NGNE N/A
- CLW 34.73
- 52 Week Low
- NGNE $6.88
- CLW $20.84
- 52 Week High
- NGNE $74.49
- CLW $33.57
- Technical
- Relative Strength Index (RSI)
- NGNE 48.86
- CLW 42.39
- Support Level
- NGNE $18.00
- CLW $21.08
- Resistance Level
- NGNE $19.93
- CLW $21.92
- Average True Range (ATR)
- NGNE 1.03
- CLW 0.61
- MACD
- NGNE 0.01
- CLW 0.27
- Stochastic Oscillator
- NGNE 55.71
- CLW 70.81
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About CLW Clearwater Paper Corporation
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.